Medicine & Life Sciences
Acute Myeloid Leukemia
100%
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
96%
Precursor Cell Lymphoblastic Leukemia-Lymphoma
63%
Imatinib Mesylate
63%
Myelodysplastic Syndromes
52%
Leukemia, Myeloid, Chronic Phase
44%
Philadelphia Chromosome
43%
Leukemia
38%
Survival
37%
Cytogenetics
36%
Protein-Tyrosine Kinases
36%
Cytarabine
34%
Therapeutics
32%
B-Cell Chronic Lymphocytic Leukemia
26%
Mutation
22%
Dasatinib
20%
Decitabine
20%
fludarabine
20%
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
20%
Primary Myelofibrosis
19%
Drug Therapy
19%
venetoclax
18%
Bone Marrow
16%
Inotuzumab Ozogamicin
15%
Neoplasms
14%
Leukemia, Myelomonocytic, Chronic
14%
blinatumomab
14%
Azacitidine
14%
GATA2 Deficiency
14%
Hematologic Neoplasms
13%
Blast Crisis
13%
Recurrence
11%
Acute Promyelocytic Leukemia
11%
Clofarabine
11%
ponatinib
11%
Interferons
11%
Stem Cell Transplantation
11%
Idarubicin
11%
Cyclophosphamide
10%
Safety
10%
INCB018424
10%
Allogeneic Cells
10%
Vincristine
9%
Chromosome Aberrations
9%
Progression-Free Survival
9%
Salvage Therapy
9%
Rituximab
8%
Residual Neoplasm
8%
Phosphotransferases
8%
Interferon-alpha
7%